No­vo Hold­ings’ $16.5B bid for Catal­ent; No­var­tis’ $2.9B bolt-on; End­points Slack in­ter­view with John Evans; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

In a week where the com­pa­ny be­hind a top obe­si­ty drug an­nounced it will buy one of the biggest con­tract man­u­fac­tur­ers of those drugs, oth­er news could pale in com­par­i­son. But there’s plen­ty of oth­er big sto­ries on deals, earn­ings, sen­ate hear­ings, peo­ple and more — see if you missed any.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER